Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA, Biosimilar Application Fees To Rise 10.7%; FDA’s Workload Adjuster Needs Work

This article was originally published in The Pink Sheet Daily

Executive Summary

Facility and product user fees will increase by more than 5% for fiscal year 2014; FDA calculated the fees using a revised workload adjuster because the previous method failed to reflect increasing complexity of the drug review process.

You may also be interested in...



PDUFA VI: Innovative Trial Design Talks Can’t Have Formal Meeting Goals, FDA Says

FDA tells industry that proposal on trials also can’t use SPA-like process.

Drug Review Personnel Costs Dropping, Remain “Completely Normal,” FDA Says

Decrease is part of a trend of increasing non-personnel expenses related to human drug review, which may indicate FDA cost containment, but also comes with another user fee increase.

FDA User Fees In FY 2014: Burden Per Application Grows As Submission Projections Fall

Agency announces new prescription drug, generic drug and biosimilar rates – with one fee increasing more than 47%.

Related Content

Topics

UsernamePublicRestriction

Register

PS076083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel